title: [Drugs for improvement of motor deficits after stroke].
abstract: Randomized controlled trials with a variety of drugs have been performed for approximately 20 years in order to support functional restitution of motor deficits after a stroke. Nowadays, serotonin reuptake inhibitors show the highest level of evidence due to the largest number of positive studies and L‑dopa also seems to be effective; however, much fewer studies have been conducted. In the majority of trials amphetamines provided no additional benefits and D‑cycloserine cannot be recommended either. Future therapeutic approaches, e.g. anti-nogo antibodies and cell therapy are presented.
authors.affiliation: Kliniken Schmieder Allensbach, Zum Tafelholz 8, 78476, Allensbach, Deutschland. j.liepert@kliniken-schmieder.de.|Lurija Institut für Rehabilitationswissenschaften und Gesundheitsforschung, Allensbach, Deutschland. j.liepert@kliniken-schmieder.de.
authors.forename: J
authors.initials: J
authors.lastname: Liepert
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003131:Combined Modality Therapy / Q000379:methods; D019317:Evidence-Based Medicine / Q000379:methods; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage; D058990:Molecular Targeted Therapy; D009069:Movement Disorders / Q000188:drug therapy* / Q000534:rehabilitation*; D009465:Neuromuscular Agents / Q000008:administration & dosage*; D017063:Outcome Assessment, Health Care / Q000379:methods; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage; D033581:Stem Cell Transplantation / Q000379:methods*; D000071939:Stroke Rehabilitation / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D007980:Levodopa; D009465:Neuromuscular Agents; D017367:Selective Serotonin Reuptake Inhibitors
keywords: Antibodies; Cell therapy; L-Dopa; Pharmacotherapy; Serotonin reuptake inhibitors